Showing 279 results

Filters Content type: News, Editors' picks Topic: Injectable & long-acting PrEP

The antiretroviral drug cabotegavir, administered every eight weeks as an injection, has been shown to be safe and effective in preventing HIV infection in men who have sex with men. Studies in women are ongoing and scientists are also working on a long-acting PrEP implant.

Injectable & long-acting PrEP

Cabotegravir HIV PrEP Effective Among U.S. Women Despite Treatment Interruptions

Editor's pick
MedPage Today (requires free registration)
5 August 2026
Heterosexual men

Mobile Men study: injectable PrEP beats pills for men who travel for work

Editor's pick
Africa Health Research Institute
5 August 2026
Access to healthcare

Lenacapavir, the revolutionary HIV drug, still hasn’t reached Latin America

Editor's pick
El País
5 August 2026
Injectable & long-acting PrEP

Gilead’s HIV PrEP franchise hits $1B quarterly sales, but analysts question Yeztugo durability

Editor's pick
FiercePharma
5 August 2026
Access to healthcare

South Africa: Some pieces falling into place for monthly HIV prevention pill, but key data not yet in

Editor's pick
Spotlight
2 August 2026
Access to healthcare

Why is Latin America still waiting for long-acting HIV prevention?

Editor's pick
Devex (requires free registration)
2 August 2026
Access to healthcare

Brazil: MSF at AIDS 2026 demanding affordable access to lenacapavir everywhere

Editor's pick
Médecins Sans Frontières
2 August 2026
Injectable & long-acting PrEP

Long-Acting Lenacapavir Still Delivered Effective HIV PrEP After a Year

Editor's pick
MedPage Today
2 August 2026
Experiences of stigma

What if “a child” sees it? Conservative Christians rage over ad about HIV prevention

Editor's pick
LGBTQ Nation
31 July 2026
Injectable & long-acting PrEP

Monthly PrEP pill could be made for US$3 a year, but Latin America is shut out of generic licensing

News
29 July 2026
Injectable & long-acting PrEP

Nearly 200,000 lenacapavir shots given across Africa, but supply issues pose challenges

News
29 July 2026
Access to healthcare

Activists React to Merck’s Voluntary License for Generic Production of Investigational Long-Acting Oral PrEP Product, Alimatravir

Editor's pick
Health GAP (Global Access Project)
27 July 2026
Injectable & long-acting PrEP

This drug could help end the HIV epidemic. Its rollout has hit speed bumps

Editor's pick
Science
27 July 2026
Access to healthcare

With Hopes High for New H.I.V. Prevention Pill, Merck Takes Steps to Ensure Access

Editor's pick
The New York Times (requires free registration)
26 July 2026
PrEP policies & guidelines

South Africa: Motsoaledi defends limited rollout of lenacapavir amid challenges

Editor's pick
IOL
16 July 2026
Access to healthcare

Accelerating Access to Long-Acting HIV Medicines: A New Roadmap for Global Health

Editor's pick
Medicines Patent Pool
8 July 2026
Pregnancy and vertical transmission

Modelling study backs targeted, not universal, lenacapavir PrEP for pregnancy and breastfeeding

News
6 July 2026
Injectable & long-acting PrEP

Closer to home: taking long-acting HIV prevention into Zambia’s communities

Editor's pick
Unitaid
24 June 2026
Injectable & long-acting PrEP

Is Kenya’s lenacapavir rollout missing young women and girls?

Editor's pick
Devex (requires free registration)
22 June 2026
Injectable & long-acting PrEP

MSF launches global campaign demanding Gilead supply HIV prevention drug for $40 a year, everywhere

Editor's pick
MSF
22 June 2026
Injectable & long-acting PrEP

All you need to know about the jab that could dramatically reduce new HIV infections in South Africa

Editor's pick
Spotlight
6 June 2026
Injectable & long-acting PrEP

South Africa Helped Create Lenacapavir, Gilead Should Not Decide Who Gets It

Editor's pick
African Alliance
6 June 2026
Injectable & long-acting PrEP

Lenacapavir (Yeytuo) injected every six months approved for HIV prevention in Canada

Editor's pick
CATIE
6 June 2026
Injectable & long-acting PrEP

How Well Is Lenacapavir PrEP Working in the Real World? It’s Complicated.

Editor's pick
TheBodyPro
6 June 2026